Kinetics of MSC-based enzyme therapy for immunoregulation.
5'-Nucleotidase
/ therapeutic use
Adenosine
/ metabolism
Adenosine Triphosphate
/ metabolism
Antigens, CD
/ therapeutic use
Apyrase
/ therapeutic use
Cell Death
Cell Proliferation
Humans
Hydrolysis
Immunomodulation
Interleukin-1beta
/ metabolism
Kinetics
Lymphocytes
/ cytology
Mesenchymal Stem Cell Transplantation
Mesenchymal Stem Cells
/ cytology
Substrate Specificity
ATP
Autoimmune disease
Cell therapy
Hydrolysis
Immune model
Immunomodulation
Inflammation
Lymphocyte
MSC
Mesenchymal stem cells
Monocyte
Pharmacokinetics
Purinergic
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
13 08 2019
13 08 2019
Historique:
received:
25
02
2019
accepted:
23
07
2019
entrez:
15
8
2019
pubmed:
15
8
2019
medline:
23
6
2020
Statut:
epublish
Résumé
Mesenchymal stromal cells (MSC) demonstrate innate and regulatory immunologic functions and have been widely explored for cell therapy applications. Mechanisms by which MSCs achieve therapeutic effects are theorized, though appropriate dosing and duration of these mechanisms in vivo warrant deeper investigation. One, rapid immunosuppressive function of MSCs is through ectoenzyme expression of CD73 and CD39 which cooperatively hydrolyze inflammatory, extracellular adenosine triphosphate (ATP) to anti-inflammatory adenosine. Extracellular ATP has a key role in autoimmune and inflammatory diseases, which administered MSCs have the potential to modulate in a timescale that is befitting of shorter acting therapeutic function. In vitro experiments were performed to determine the hydrolysis rates of ATP by MSCs. Through kinetic modeling from experimental results, the rate at which a single cell can metabolize ATP was determined. Based on these rates, the ability of MSCs to downregulate inflammatory signaling pathways was prospectively validated using model system parameters with respect to two different mechanisms: extracellular ATP stimulates lymphocytes to suppress proliferation and induce apoptosis and with co-stimulation, it stimulates monocytes to release pro-inflammatory IL-1β. MSCs were co-cultured with immune cells using transwell inserts and compared to immune cell only groups. Hydrolysis of ATP was efficiently modeled by first-order enzyme kinetics. For in vitro culture, the rate at which a single cell can hydrolyize ATP is 8.9 nmol/min. In the presence of extracellular ATP, cocultures of MSCs reduced cytotoxicity and allows for proliferation of lymphocytes while limiting IL-1β secretion from monocytes. Such use of these models may allow for better dosing predictions for MSCs to be used therapeutically for chronic inflammatory diseases such as rheumatoid arthritis, diabetes, pancreatitis, and other systemic inflammatory response syndromes. For the first time, the effect of MSCs on ATP hydrolysis in immune cell response is quantitatively analyzed on a cell-molecule basis by modeling the hydrolysis as an enzyme-substrate reaction. The results also give insight into MSCs' dynamic response mechanisms to ameliorate effects of extracellular ATP whether it be through positive or negative regulation.
Sections du résumé
BACKGROUND
Mesenchymal stromal cells (MSC) demonstrate innate and regulatory immunologic functions and have been widely explored for cell therapy applications. Mechanisms by which MSCs achieve therapeutic effects are theorized, though appropriate dosing and duration of these mechanisms in vivo warrant deeper investigation. One, rapid immunosuppressive function of MSCs is through ectoenzyme expression of CD73 and CD39 which cooperatively hydrolyze inflammatory, extracellular adenosine triphosphate (ATP) to anti-inflammatory adenosine. Extracellular ATP has a key role in autoimmune and inflammatory diseases, which administered MSCs have the potential to modulate in a timescale that is befitting of shorter acting therapeutic function.
METHODS
In vitro experiments were performed to determine the hydrolysis rates of ATP by MSCs. Through kinetic modeling from experimental results, the rate at which a single cell can metabolize ATP was determined. Based on these rates, the ability of MSCs to downregulate inflammatory signaling pathways was prospectively validated using model system parameters with respect to two different mechanisms: extracellular ATP stimulates lymphocytes to suppress proliferation and induce apoptosis and with co-stimulation, it stimulates monocytes to release pro-inflammatory IL-1β. MSCs were co-cultured with immune cells using transwell inserts and compared to immune cell only groups.
RESULTS
Hydrolysis of ATP was efficiently modeled by first-order enzyme kinetics. For in vitro culture, the rate at which a single cell can hydrolyize ATP is 8.9 nmol/min. In the presence of extracellular ATP, cocultures of MSCs reduced cytotoxicity and allows for proliferation of lymphocytes while limiting IL-1β secretion from monocytes.
CONCLUSIONS
Such use of these models may allow for better dosing predictions for MSCs to be used therapeutically for chronic inflammatory diseases such as rheumatoid arthritis, diabetes, pancreatitis, and other systemic inflammatory response syndromes. For the first time, the effect of MSCs on ATP hydrolysis in immune cell response is quantitatively analyzed on a cell-molecule basis by modeling the hydrolysis as an enzyme-substrate reaction. The results also give insight into MSCs' dynamic response mechanisms to ameliorate effects of extracellular ATP whether it be through positive or negative regulation.
Identifiants
pubmed: 31409424
doi: 10.1186/s12967-019-2000-6
pii: 10.1186/s12967-019-2000-6
pmc: PMC6693124
doi:
Substances chimiques
Antigens, CD
0
Interleukin-1beta
0
Adenosine Triphosphate
8L70Q75FXE
5'-Nucleotidase
EC 3.1.3.5
Apyrase
EC 3.6.1.5
CD39 antigen
EC 3.6.1.5
Adenosine
K72T3FS567
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
263Subventions
Organisme : NIH HHS
ID : R01GM127353
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM135141
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008339
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32GM008339
Pays : United States
Organisme : NIBIB NIH HHS
ID : R01 EB012521
Pays : United States
Organisme : NIH HHS
ID : R01EB012521
Pays : United States
Références
Front Biosci (Schol Ed). 2011 Jun 01;3:1443-56
pubmed: 21622280
Ann Rheum Dis. 2012 Oct;71(10):1630-5
pubmed: 22966146
Cell Transplant. 2011;20(8):1221-30
pubmed: 21176405
Front Immunol. 2015 Feb 12;6:54
pubmed: 25729382
Arthritis Rheum. 2013 May;65(5):1181-93
pubmed: 23400582
J Immunol. 1997 Aug 1;159(3):1451-8
pubmed: 9233643
Sci Signal. 2009 Feb 03;2(56):pe6
pubmed: 19193605
Stem Cells Dev. 2013 Nov 1;22(21):2825-35
pubmed: 23767885
Transplantation. 2003 Feb 15;75(3):389-97
pubmed: 12589164
J Intern Med. 2007 Nov;262(5):509-25
pubmed: 17949362
Leukemia. 2007 Aug;21(8):1733-8
pubmed: 17541394
Blood. 2003 May 1;101(9):3722-9
pubmed: 12506037
Front Immunol. 2017 Nov 20;8:1577
pubmed: 29209319
Blood. 2014 Jan 23;123(4):594-5
pubmed: 24458278
Blood. 2002 May 15;99(10):3838-43
pubmed: 11986244
Stem Cells. 2009 Jan;27(1):259-65
pubmed: 18832595
Trends Pharmacol Sci. 2007 Sep;28(9):465-72
pubmed: 17692395
Front Pharmacol. 2018 Feb 06;9:52
pubmed: 29467654
J Transl Med. 2016 Aug 26;14(1):246
pubmed: 27565858
Exp Hematol. 2002 Jan;30(1):42-8
pubmed: 11823036
Purinergic Signal. 2014;10(2):357-65
pubmed: 24043462
Stem Cells. 2007 Apr;25(4):1021-8
pubmed: 17170063
Blood. 2005 Feb 15;105(4):1815-22
pubmed: 15494428
Nature. 2008 Oct 9;455(7214):808-12
pubmed: 18716618
Transplantation. 2006 May 27;81(10):1390-7
pubmed: 16732175
Pharmacol Ther. 2006 Nov;112(2):358-404
pubmed: 16784779
J Biol Chem. 2013 Jun 28;288(26):19040-9
pubmed: 23677997
J Immunol. 2012 Aug 1;189(3):1303-10
pubmed: 22753942
Trans Am Clin Climatol Assoc. 2007;118:199-208
pubmed: 18528503
Stem Cell Res. 2011 Jul;7(1):66-74
pubmed: 21546330
J Transl Med. 2011 Oct 21;9:181
pubmed: 22017805
Blood Cells Mol Dis. 2008 Jan-Feb;40(1):25-32
pubmed: 17869550
J Immunol. 2006 Feb 15;176(4):2279-91
pubmed: 16455984
J Bone Joint Surg Am. 2004 Jul;86(7):1541-58
pubmed: 15252108
Scand J Immunol. 2003 Jan;57(1):11-20
pubmed: 12542793